Plasma fibroblast growth factor 23 concentration and iron status. Does the relationship exist in the elderly population?

Clinical Biochemistry

Volumn 48, Issue 6, 2015, Pages 431-436

  Bozentowicz Wikarek, Maria ^a   Kocełak, Piotr ^a   Owczarek, Aleksander ^a   Olszanecka Glinianowicz, Magdalena ^a   Mossakowska, Małgorzata ^b   Skalska, Anna ^c   Wiecek, Andrzej ^a   Chudek, Jerzy ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

^b INTERNATIONAL INSTITUTE OF MOLECULAR AND CELL BIOLOGY   (Poland)

^c JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

Author keywords

Aging; CFGF23; Ferritin; IFGF23; Inflammation; Iron status

Indexed keywords

BIOLOGICAL MARKER; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 23; IRON;

AGED; BLOOD; FEMALE; HUMAN; IRON DEFICIENCY ANEMIA; MALE; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; BIOMARKERS; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; IRON; MALE;

EID: 84939943223     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2014.12.027     Document Type: Article

References (38)

1. De Beur S.M., Finnegan R.B., Vassiliadis J., Cook B., Barberio D., Estes S., et al. Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J Bone Miner Res 2002, 17:1102-1110.
2. White K.E., Carn G., Lorenz-Depiereux B., Benet-Pages A., Strom T.M., Econs M.J. Autosomal-dominant hypophosphatemic rickets (ADHR) mutations stabilize FGF-23. Kidney Int 2001, 60:2079-2086.
3. Yamazaki Y., Okazaki R., Shibata M., Hasegawa Y., Satoh K., Tajima T. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab 2002, 87:4957-4960.
4. Filler G., Liu D., Huang S.H., Casier S., Chau L., Madrenas J. Impaired GFR is the most important determinant for fgf-23 increase in chronic kidney disease. Clin Biochem 2011, 44:435-437.
5. Fliser D., Kollerits B., Neyer U., Ankerst D.P., Lhotta K., Lingenhel A., et al. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) Study. J Am Soc Nephrol 2007, 18:2600-2608.
6. Gutierrez O., Isakova T., Rhee E., Shah A., Holmes J., Collerone G., et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005, 16:2205-2215.
7. Larsson T., Nisbeth U., Ljunggren O., Jüppner H., Jonsson K.B. Circulating concentration of FGF-23 increases as renal function declines in patients with chronic kidney disease, but does not change in response to variation in phosphate intake in healthy volunteers. Kidney Int 2003, 64:2272-2279.
8. Schouten B.J., Hunt P.J., Livesey J.H., Frampton C.M., Soule S.G. FGF23 elevation and hypophosphatemia after intravenous iron polymaltose: a prospective study. J Clin Endocrinol Metab 2009, 94:2332-2337.
9. Schouten B.J., Doogue M.P., Soule S.G., Hunt P.J. Iron polymaltose-induced FGF23 elevation complicated by hypophosphataemic osteomalacia. Ann Clin Biochem 2009, 46:167-169.
10. Takeda Y., Kamara H., Goto S., Fujii H., Umezu M., Hasegawa H., et al. Effect of intravenous saccharated ferric oxide on serum FGF23 and mineral metabolism in hemodialysis patients. Am J Nephrol 2011, 33:421-426.
11. Deger S.M., Erten Y., Pasaoglu O.T., Derici U.B., Reis K.A., Onec K., et al. The effects of iron on FGF23-mediated Ca-P metabolism in CKD patients. Clin Exp Nephrol 2013, 17:416-423.
12. Braithwaite V., Prentice A.M., Doherty C., Prentice A. FGF23 is correlated with iron status but not with inflammation and decreases after iron supplementation: a supplementation study. Int J Pediatr Endocrinol 2012, 1:27.
13. Shimizu Y., Tada Y., Yamauchi M., Okamoto T., Suzuki H., Ito N., et al. Hypophosphatemia induced by intravenous administration of saccharated ferric oxide: another form of FGF23-related hypophosphatemia. Bone 2009, 45:814-816.
14. Imel E.A., Peacock M., Gray A.K., Padgett L.R., Hui S.L., Econs M.J. Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J Clin Endocrinol Metab 2011, 96:3541-3549.
15. Farrow E.G., Yu X., Summers L.J., Davis S.I., Fleet J.C., Allen M.R., et al. Iron deficiency drives an autosomal dominant hypophosphatemic rickets (ADHR) phenotype in fibroblast growth factor-23 (Fgf23) knock-in mice. Proc Natl Acad Sci U S A 2011, 108:1146-1155.
16. Braithwaite V., Jarjou L.M.A., Goldberg G.R., Prentice A. Iron status and fibroblast growth factor-23 in Gambian children. Bone 2012, 50:1351-1356.
17. The Scientific Advisory Committee on Nutrition Iron and health United Kingdom 2010, The Stationary Office, London.
18. Durham B.H., Joseph F., Bailey L.M., Fraser W.D. The association of circulating ferritin with serum concentrations of fibroblast growth factor-23 measured by three commercial assays. Ann Clin Biochem 2007, 44:463-466.
19. Bhattacharyya N., Wiench M., Dumitrescu C., Connolly B.M., Bugge T.H., Patel H.V., et al. Mechanism of FGF23 processing in fibrous dysplasia. J Bone Miner Res 2012, 27:1132-1141.
20. Holecki M., Chudek J., Owczarek A., Olszanecka-Glinianowicz M., Boz˙entowicz-Wikarek Duława J., et al. Inflammation but not nutritional status or insulin resistance is associated with plasma fibroblast growth factor 23 concentration in the elderly. Clin Endocrinol (Oxf) 2015, [submitted].
21. Błedowski P., Mossakowska M., Chudek J., Grodzicki T., Milewicz A., Szybalska A., et al. Medical, psychological, social, and economic aspects of aging in Poland (Polsenior): research assumptions and objectives. Exp Gerontol 2011, 46(12):1003-1009.
22. Levey A.S., Stevens L.A., Schmid C.H., Zhang Y.L., Castro A.F., Feldman H.I., et al. CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration). A new equation to estimate glomerular filtration rate. Ann Intern Med 2009, 150:604-612.
23. Eckardt K.U., Berns J.S., Rocco M.V., Kasiske B.L. Definition and classification of CKD: the debate should be about patient prognosis-a position statement from KDOQI and KDIGO. Am J Kidney Dis 2009, 53:915-920.
24. Levey A., Eckardt K.U., Tsukamoto Y., Levin A., Coresh J., Rossert J., et al. Definition and classification of chronic kidney disease: a position statement from Kidney Disease: Improving Global Outcomes (KDIGO). Kidney Int 2005, 67:2089-2100.
25. Łeski J.M., Owczarek A.J. A time-dominant-constrained fuzzy clustering method and its application to signal analysis. Fuzzy Sets Syst 2005, 155:165-190.
26. Díaz-Castro J., López-Frías M.R., Campos M.S., López-Frías M., Alférez M.J., Nestares T., et al. Severe nutritional iron-deficiency anemia has a negative effect on some bone turnover biomarkers in rats. Eur J Nutr 2012, 51:241-247.
27. Katsumata S., Katsumata-Tsuboi R., Uehara M., Suzuki K. Severe iron deficiency decreases both bone formation and bone resorption in rats. J Nutr 2009, 139:238-243.
28. Wolf M., Koch T.A., Bregman D.B. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J Bone Miner Res 2013, 28:1793-1803.
29. McGillivray G., Skull S.A., Davie G., Kofoed S.E., Frydenberg A., Rice J., et al. High prevalence of asymptomatic vitamin D and iron deficiency in East African immigrant children and adolescents living in a temperate climate. Arch Dis Child 2007, 92:1088-1093.
30. Grindulis H., Scott P.H., Belton N.R., Wharton B.A. Combined deficiency of iron and vitamin D in Asian toddlers. Arch Dis Child 1986, 61:843-848.
31. Sim J.J., Lac P.T., Liu I.L., Meguerditchian S.O., Kumar V.A., Kujubu D.A., et al. Vitamin D deficiency and anemia: a cross-sectional study. Ann Hematol 2010, 89:447-452.
32. Jones G., Strugnell S.A., DeLuca H.F. Current understanding of the molecular actions of vitamin D. Physiol Rev 1998, 78:1193-1231.
33. DeLuca H.F. Metabolism of vitamin D: current status. Am J Clin Nutr 1976, 29:1258-1270.
34. Tanaka H., Teitelbaum S.L. Vitamin D regulates transferrin receptor expression by bone marrow macrophage precursors. J Cell Physiol 1990, 145:303-309.
35. Norman A.W. Minireview: vitamin D receptor: new assignments for an already busy receptor. Endocrinology 2006, 147:5542-5548.
36. Blanco-Rojo R., Pérez-Granados A.M., Toxqui L., Zazo P., de la Piedra C., Vaquero M.P. Relationship between vitamin D deficiency, bone remodelling and iron status in iron-deficient young women consuming an iron-fortified food. Eur J Nutr 2013, 52:695-703.
37. Heldenberg D., Tenenbaum G., Weisman Y. Effect of iron on serum 25-hydroxyvitamin D and 24,25-dihydroxyvitamin D concentrations. Am J Clin Nutr 1992, 56:533-536.
38. Naiman J.L., Oski F.A., Diamond L.K., Vawter G.F., Shwachman H. The gastrointestinal effects of iron-deficiency anemia. Pediatrics 1964, 33:83-99.